Horsham, PA, United States

Galleon Pharmaceuticals

www.galleonpharma.com
Horsham, PA, United States
SEARCH FILTERS
Time filter
Source Type

— Obstructive Sleep Apnea Pipeline Market Companies Involved in Therapeutics Development are Galleon Pharmaceuticals Inc, RespireRx Pharmaceuticals Inc, SK Biopharmaceuticals Co Ltd and Vivus Inc. Obstructive sleep apnea is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. Signs and symptoms of obstructive sleep apnea include excessive daytime sleepiness, awakening with chest pain, morning headache, high blood pressure, awakening with a dry mouth. Risk factors include being overweight, hypertension, diabetes, gender, smoking and family history. This research provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Inquire more about this research at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=774096 The Obstructive Sleep Apnea (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively. Obstructive Sleep Apnea (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Buy a copy of this research at http://www.reportsnreports.com/purchase.aspx?name=774096 • The pipeline guide provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea (Respiratory). • The pipeline guide reviews pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Obstructive Sleep Apnea (Respiratory) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Obstructive Sleep Apnea (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Obstructive Sleep Apnea (Respiratory). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Obstructive Sleep Apnea (Respiratory) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. For more information, please visit http://www.reportsnreports.com/reports/774096-obstructive-sleep-apnea-pipeline-review-h2-2016.html


Patent
Galleon Pharmaceuticals | Date: 2011-03-08

The invention relates to compounds, compositions, and methods for diminishing pain in a subject in need thereof comprising administering the compounds and compositions herein described.


The present invention includes compounds, and compositions comprising the same, that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention.


Patent
Galleon Pharmaceuticals | Date: 2014-03-13

The present invention includes pyrimido[5,4-d]pyrimidines that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention.


The present invention includes compositions that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition of the invention.


The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.


The present invention includes a composition comprising a compound, such as a 2,4,6-triamino-1,3,5-triazine, 2,4,6-triaminopyrimidine, 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine or 2,4-diamino-7H-pyrrolo[2,3-d]pyrimidine, that is useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention. The present invention further includes a method of preventing destabilizing or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of the invention.


ReportsnReports.com offers EpiCast Report: Insomnia - Epidemiology Forecast to 2023 report to its store. The report provides an overview of the risk factors, comorbidities and the global and historical trends for insomnia in the seven major markets (7MM). Epidemiologists forecast that the total prevalent cases of acute insomnia in the 7MM will increase from 121,799,911 total prevalent cases in 2013, to 130,482,156 total prevalent cases in 2023 at an Annual Growth Rate (AGR) of 0.71%. GlobalData epidemiologists forecast an increase in the total prevalent cases of chronic insomnia (not fulfilling DSM-IV criteria) in the 7MM from 62,982,390 total prevalent cases in 2013, to 67,471,957 total prevalent cases in 2023 at an AGR of 0.71%. The 7MM had an estimated 23,690,040 total prevalent cases of chronic primary insomnia in 2013 and the number of total prevalent cases is expected to increase to 25,378,728 by 2023, at an AGR of 0.71%. GlobalData epidemiologists forecast that the total prevalent cases of chronic secondary insomnia in the 7MM will increase from 53,697,425 total prevalent cases in 2013, to 57,525,122 total prevalent cases in 2023 at an AGR of 0.71%. Complete report with TOC is available @ http://www.reportsnreports.com/reports/344994-epicast-report-insomnia-epidemiology-forecast-to-2023.html . Insomnia is a highly prevalent condition; approximately one third of the general population presents with some degree of insomnia. Epidemiologists used comprehensive country-specific data from population-based studies published in peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia in the 7MM, based on the DSM-IV criteria. For all the 7MM, the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia were segmented by age and sex, which facilitates an understanding of the distribution of the disease within the population and informs strategies to improve the management of the disease. Furthermore, the forecast methodology is consistent across each of the 7MM, thereby allowing for a meaningful comparison of the forecast total prevalent cases among each market. Order a Purchase copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=344994 . (This is a premium report priced at US$3995 for a single user License.) Scope of this report cover: The Insomnia EpiCast Report providess an overview of the risk factors, comorbidities, and the global and historical trends for insomnia in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases of acute insomnia, chronic insomnia (not fulfilling DSM-IV criteria), chronic primary insomnia, and chronic secondary insomnia, segmented by sex and age (in 15-year age groups beginning at 15 years and ending at =75 years) in these markets. The insomnia epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM. Explore more reports of Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ . This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. Companies discussed in this report include Cortex Pharmaceuticals, Inc., Galleon Pharmaceuticals, Rottapharm SpA, SK Biopharmaceuticals Co., Ltd. This report provides elemental information and data relating to the clinical trials on Obstructive Sleep Apnea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Obstructive Sleep Apnea. Companies discussed in this report include Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Phillips Respironics International Inc., Cortex Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Chemical Holdings Corporation, Fisher & Paykel Healthcare Corporation Limited and BIOPROJET SCR. About Us: ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.


News Article | August 4, 2015
Site: www.businesswire.com

HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals, the first company to build a drug discovery and development platform focusing on pharmaceuticals for sleep apnea and related breathing-control disorders, announced today that it has named Joseph Oliveto as Chief Executive Officer, effective immediately. Mr. Oliveto replaces James C. Mannion, Ph.D., who will retire as CEO and continue to serve as a strategic advisor to the company. Mr. Oliveto brings more than 25 years of pharmaceutical and biotech experience across the areas of drug development, commercialization, manufacturing and business development. Most recently, Mr. Oliveto served as President and CEO of Chelsea Therapeutics, a publicly held biopharmaceutical company. During his tenure as CEO, he led the company through the FDA’s approval of Northera™ for the treatment of neurogenic orthostatic hypotension, and the subsequent sale of Chelsea to Lundbeck, Inc. “Joe’s broad experience and proven track record in leading successful R&D and commercial teams will be of great value as we continue to build upon Galleon’s success to date,” said Thomas J. Dietz, Ph.D., Chairman of Galleon Pharmaceuticals. “At the same time, we want to recognize the outstanding work that Jim Mannion did since founding the company as CEO. Thanks to his leadership and vision, Galleon is well-positioned to continue clinical studies and eventually bring these investigational therapies to market.” “I’m honored to join Galleon’s management team,” said Mr. Oliveto. “Galleon is in the midst of exciting research and development to satisfy critical unmet medical needs in sleep apnea patients, and the potential of the company is clearly evidenced by the strength of its clinical data. I look forward to bringing my development and commercial experience to an already strong team in order to achieve our goals of advancing clinical compounds to market approval and commercialization.” Prior to joining Chelsea, Mr. Oliveto held progressively senior operating roles at Hoffmann-LaRoche across the areas of drug development, manufacturing, global business and business development. He played a major part in the success of multiple NDA approvals, developed comprehensive launch programs, and closed multiple licensing agreements. Mr. Oliveto holds a BA in Chemistry and an MBA, both from Rutgers University. Galleon is the first company to build a drug discovery and development platform that focuses on the pharmaceutical treatment of sleep apnea and related breathing-control disorders. The company’s proprietary platform incorporates recent advances in neurobiology, molecular physiology, respiratory medicine and medicinal chemistry. Galleon has developed proprietary models of sleep apnea and breathing control that enable a multi-dimensional analysis of the primary causes of sleep apnea and related conditions. For more information, please visit us.


DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t5zcl3/sleep_apnea) has announced the addition of the "Sleep Apnea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Loading Galleon Pharmaceuticals collaborators
Loading Galleon Pharmaceuticals collaborators